12 results on '"Mammar, Hamid"'
Search Results
2. Tumor Growth Rate as a New Predictor of Progression-Free Survival After Chordoma Surgery.
- Author
-
Passeri, Thibault, Russo, Paolo di, Champagne, Pierre-Olivier, Bernat, Anne-Laure, Cartailler, Jérome, Guichard, Jean Pierre, Mammar, Hamid, Giammattei, Lorenzo, Adle-Biassette, Homa, George, Bernard, Mandonnet, Emmanuel, and Froelich, Sébastien
- Published
- 2021
- Full Text
- View/download PDF
3. Tumor Growth Rate as a New Predictor of Progression-Free Survival After Chordoma Surgery
- Author
-
Passeri, Thibault, di Russo, Paolo, Champagne, Pierre-Olivier, Bernat, Anne-Laure, Cartailler, Jérome, Guichard, Jean Pierre, Mammar, Hamid, Giammattei, Lorenzo, Adle-Biassette, Homa, George, Bernard, Mandonnet, Emmanuel, and Froelich, Sébastien
- Abstract
Graphical Abstract
- Published
- 2021
- Full Text
- View/download PDF
4. Tumor Growth Rate as a New Predictor of Progression-Free Survival After Chordoma Surgery.
- Author
-
Passeri, Thibault, di Russo, Paolo, Champagne, Pierre-Olivier, Bernat, Anne-Laure, Cartailler, Jérome, Guichard, Jean Pierre, Mammar, Hamid, Giammattei, Lorenzo, Adle-Biassette, Homa, George, Bernard, Mandonnet, Emmanuel, and Froelich, Sébastien
- Abstract
Currently, different postoperative predictors of chordoma recurrence have been identified. Tumor growth rate (TGR) is an image-based calculation that provides quantitative information of tumor's volume changing over time and has been shown to predict progression-free survival (PFS) in other tumor types.
- Published
- 2021
- Full Text
- View/download PDF
5. Pharmacokinetic Analysis of [18F]FAZA Dynamic PET Imaging Acquisitions for Highlighting Sacrum Tumor Profiles
- Author
-
Provost, Claire, Mammar, Hamid, Belly-Poinsignon, Anne, Madar, Olivier, and Champion, Laurence
- Abstract
A patient enrolled in a clinical trial (NCT02802969) with suspicion of chordoma underwent an [18F]FAZA PET/CT, a radiolabeled nitroimidazole analog of hypoxia PET imaging. The patient's images showed a different tumor profile compared to those observed in other hypoxic or nonhypoxic chordoma patients. The motivation for using [18F]FAZA pharmacokinetic imaging was to compare this profile with histologically confirmed cases of chordoma. Through visual imaging and quantification of blood and tumor time-activity curves, we excluded the hypothesis that it was a chordoma, diagnosing a paraganglioma.
- Published
- 2020
- Full Text
- View/download PDF
6. La protonthérapie comme modalité d’irradiation dans les sarcomes des os ou cartilage et des tissus mous, état des lieux en 2018
- Author
-
Thariat, Juliette, Tessonnier, Thomas, Bonvalot, Sylvie, Lerouge, Delphine, Mammar, Hamid, Bolle, Stephanie, Claren, Audrey, Duffaud, Florence, Alapetite, Claire, and Vogin, Guillaume
- Abstract
Les sarcomes sont un type de tumeur fréquent dans la population pédiatrique. Du fait de l’épargne tissulaire qu’elle réalise, la protonthérapie est une indication préférentielle en pédiatrie par rapport à d’autres modalités d’irradiation en photons. La protonthérapie est également une technique d’irradiation validée phare et historique dans les chondrosarcomes et chordomes de la base du crâne et du rachis. Du fait des caractéristiques physiques des protons, la protonthérapie peut potentiellement limiter les volumes de tissus sains irradiés chez l’adulte et limiter le risque de toxicités aiguës et tardives. L’évaluation du niveau de preuve de la protonthérapie dans les sarcomes est en cours à travers des études prospectives dont un nombre croissant d’études randomisées dans les situations cliniques constituant des indications potentielles (larges volumes, réirradiation, bas grade, etc.).
- Published
- 2018
- Full Text
- View/download PDF
7. 18F-Choline PET/CT Imaging for Intracranial Hemangiopericytoma Recurrence
- Author
-
Jehanno, Nina, Cassou-Mounat, Thibaut, Mammar, Hamid, Luporsi, Marie, and Huchet, Virginie
- Abstract
We report the case of a 50-year-old man, with previous history of grade 3 intracranial hemangiopericytoma with initial complete surgical resection, addressed for local recurrence. Surgical revision performed 18 months after initial surgery allowed only partial resection, leaving residual disease along the optic nerve. Complementary radiotherapy with proton was decided. 18F-FDG PET/CT and 18F-choline PET/CT were both performed for treatment planning. 18F-FDG PET showed no uptake of the residual tumor, whereas 18F-choline depicted highly metabolic residual disease uptake with excellent delineation of local recurrence. 18F-choline PET/CT appears as a useful PET tracer for hemagiopericytoma imaging.
- Published
- 2019
- Full Text
- View/download PDF
8. Proton beam therapy in the management of central nervous system tumors in childhood: The preliminary experience of the Centre de Protonthérapie d'Orsay
- Author
-
Noel, Georges, Habrand, Jean-Louis, Helfre, Sylvie, Mammar, Hamid, Kalifa, Chantal, Ferrand, Régis, Beaudre, Anne, and Gaboriaud, Geneviève
- Abstract
The purpose of the study was to evaluate clinical results and complications of a combination of proton and photon irradiation administered to 17 children with selected central nervous system (CNS) tumors. Between July 1994 and September 2000, 17 children, aged from 5 to 17 years (median: 12 years) with intracranial benign (6 cases) or malignant (11 cases) tumors, were treated with photons (median dose: 40 Gy; 2454) and protons (median dose: 20 CGE; 931) at the Centre de Protonthérapie d'Orsay (CPO). Mean follow-up was 27 months (381). Two patients recurred locally (one marginal and one in situ). Fifteen patients are alive and doing well. Overall, 12, 24, and 36-month local control rate was 92 ± 8% and, 12, 24, and 36-month overall survival rates were 93 ± 6%, 83 ± 11%, and 83 ± 11%, respectively. Clinical initial symptoms remained stable or subsided in all patients. Early toxicities were in the expected range. With a mean 27 months follow-up, protontherapy was well tolerated for doses upto 69 CGE and with an excellent local control rate. Med Pediatr Oncol 2003;40:309315. © 2003 Wiley-Liss, Inc.
- Published
- 2003
- Full Text
- View/download PDF
9. Radiation Therapy for Chordoma and Chondrosarcoma of the Skull Base and the Cervical Spine
- Author
-
Noël, Georges, Habrand, Jean-Louis, Jauffret, Eric, Crevoisier, Renaud de, Dederke, Sygon, Mammar, Hamid, Haie-Méder, Christine, Pontvert, Dominique, Hasboun, Dominique, Ferrand, Régis, Boisserie, Gilbert, Beaudré, Anne, Gaboriaud, Geneviève, Guedea, Ferran, Petriz, Lourdes, and Mazeron, Jean-Jacques
- Abstract
Background: Prospective analysis of local tumor control, survival and treatment complications in 67 consecutive patients treated with fractionated photon and proton radiation for chordoma or chondrosarcoma of the base of the skull and the cervical spine. Patients and Methods: Between December 1995 and January 2000, 67 patients with a median age of 52 years (range: 14-85 years), were treated at the Centre de Protonthérapie d'Orsay (CPO), France, using the 201-MeV proton beam, 49 for chordoma and 18 for chondrosarcoma. Irradiation combined high-energy photons and protons. Photons represented two thirds of the total dose and protons one third. The median total dose delivered within gross tumor volume (GTV) was 67 Cobalt Gray Equivalents (CGE; range: 60-70 CGE). Results: Within a median follow-up of 29 months (range: 4-71 months), the 3-year local control rates were 71% and 85% for chordomas and chondrosarcomas, respectively, and the 3-year overall survival rates 88% and 75%, respectively. 14 tumors (21.5%) failed locally (eight within the GTV, four within the clinical target volume [CTV], and two without further assessment). Seven patients died from their tumor and another one from a nonrelated condition (pulmonary embolism). The maximum tumor diameter and, similarly, the GTV were larger in relapsing patients, compared with the rest of the population: 56 mm vs 44 mm (p = 0.024) and 50 ml vs 22 ml (p = 0.0083), respectively. In univariate analysis, age ≤ 52 years at the time of radiotherapy (p = 0.002), maximum diameter < 45 mm (p = 0.02), and GTV < 28 ml (p = 0.02) impacted positively on local control. On multivariate analysis, only age was an independent prognostic factor of local control. Conclusion: In chordomas and chondrosarcomas of the skull base and cervical spine, combined photon and proton radiation therapy offers excellent chances of cure. In two thirds of the cases, relapses are located in the GTV. Maximum diameter, GTV, and age are prognostic indicators of local control. These results should be confirmed during a longer follow-up. Hintergrund: Prospektive Analyse der lokalen Tumorkontrolle, Überlebenszeit und Behandlungsfolgen bei 67 Patienten mit einem Chordom oder Chondrosarkom der Schädelbasis und im Bereich der Halswirbelsäule, die mit einer fraktionierten Strahlentherapie mit Protonen und Photonen behandelt wurden. Patienten und Methodik: Zwischen Dezember 1995 und Januar 2000 wurden am Centre de Protonthérapie d'Orsay, Frankreich, 67 Patienten mit 201-MeV-Protonen behandelt. 49 Patienten wiesen ein Chordom und 18 ein Chondrosarkom auf. Das mediane Alter betrug 52 Jahre (14-85 Jahre). Die Strahlentherapie wurde kombiniert mit hochenergetischen Photonen und Protonen durchgeführt. Der Dosiseintrag erfolgt zu zwei Drittel durch die Photonen und zu einem Drittel durch die Protonen. Die applizierte Gesamtdosis im GTV betrug 67 Cobalt Gray Equivalents (CGE; 60-70 CGE). Ergebnisse: Im medianen Nachbeobachtungszeitraum von 29 Monaten (4-71 Monate) betrugen die lokale Kontrollrate nach 3 Jahren 71% bzw. 85% sowie die 3-Jahres-Gesamtüberlebenszeit 88% bzw. 75% für Chordome bzw. Chondrosarkome. 14 Patienten (21,5%) rezidivierten lokal (acht im GTV, vier im CTV und zwei ohne nähere Angaben). Sieben Patienten verstarben am Tumor und ein weiterer an einer interkurrenten Erkrankung. Der maximale Tumordurchmesser war bei Patienten mit Rezidiv im Vergleich zu Patienten ohne Rezidiv größer: 59 mm vs. 44 mm (p = 0,024) bzw. 50 ml vs. 22 ml (p = 0,0083). In der univariaten Analyse zeigte sich ein positiver Einfluss auf die lokale Kontrollrate bei einem Alter ≤52 Jahre zu Bestrahlungsbeginn (p = 0,002), einem maximalen Tumordurchmesser < 45 mm (p = 0,02) und einem GTV < 28 ml (p = 0,02). In der multivariaten Analyse erwies sich nur noch das Alter als unabhängiger prognostischer Faktor der lokalen Kontrolle. Schlussfolgerung: Bei Chordomen und Chondrosarkomen der Schädelbasis und im Bereich der Halswirbelsäule bietet die kombinierte Strahlentherapie mit Photonen und Protonen exzellente Heilungschancen. Zwei Drittel der Rezidive treten im GTV auf. Der maximale Tumordurchmesser, das GTV und das Alter waren die prognostischen Faktoren der lokalen Kontrolle. Die Ergebnisse sollten über einen längeren Beobachtungszeitraum bestätigt werden.
- Published
- 2003
- Full Text
- View/download PDF
10. Highly Conformal Therapy Using Proton Component in the Management of Meningiomas
- Author
-
Noël, Georges, Habrand, Jean-Louis, Mammar, Hamid, Haie-Meder, Christine, Pontvert, Dominique, Dederke, Sygon, Ferrand, Régis, Beaudré, Anne, Gaboriaud, Geneviève, Boisserie, Gibert, and Mazeron, Jean-Jacques
- Abstract
Aims: To evaluate the efficacy and the tolerance of an escalated dose of external conformal fractionated radiation therapy combining photons and protons in the treatment of intracranial meningiomas. Patients and Methods: Between December 1995 and December 1999, 17 patients received a treatment by 201-MeV proton beam at the Centre de Protonthérapy d'Orsay (CPO) for a meningioma. Five patients presented a histologically atypical or malignant meningioma, twelve patients a benign one that was recurrent or rapidly progressive. In two cases radiotherapy was administered in the initial course of the disease and in 15 cases at the time of relapse. A highly conformal approach was used combining high-energy photons and protons for approximately 2/3 and 1/3 of the total dose. The median total dose delivered within gross tumor volume was 61 Cobalt Gray Equivalent CGE (25-69). Results: Median follow-up was 37 months (17-60). The 4-year local control and overall survival rates were 87.5 ± 12% and 88.9 ± 11%, respectively. One patient failed locally within the clinical tumor volume. One patient died of intercurrent disease. A complete or partial clinical improvement was seen in most of patients. Radiologically, there were eleven stable diseases and five partial responses. In 12/15 recurrent cases, the free interval after radiotherapy is longer than that achieved by the initial surgery. This radiotherapy was well tolerated. Conclusions: In both benign and more aggressive meningiomas, the combination of conformal photons and protons with a dose escalated by 10-15% offers clinical improvements in most patients as well as radiological long-term stabilization. Ziel: Evaluierung der Effizienz sowie der Toleranz einer Dosiseskalation einer fraktionierten konformalen Strahlentherapie kombiniert mit Photonen und Protonen bei der Behandlung intrakranieller Meningeome. Patienten und Methode: Zwischen Dezember 1995 und Dezember 1999 wurden 17 Patienten mit einem Meningeom mit Protonen der Energie 201 MeV im Centre de Protonthérapie d'Orsay (CPO) behandelt. Fünf Patienten hatten ein histologisch atypisches oder malignes Meningeom; zwölf Patienten mit einem gutartigen Meningeom zeigten Rezidive oder eine rasche Progression. In zwei Fällen erfolgte die Bestrahlung primär und in 15 Fällen zum Zeitpunkt des Rezidivs bzw. der Progression. Eine konformale Technik wurde benutzt, kombiniert mit hochenergetischen Photonen und Protonen mit ungefähr 2/3 zu 1/3 der Gesamtdosis. Die applizierte Dosis im GTV betrug im Median 61 (25-69) Cobalt Gray Equivalent (CGE). Ergebnisse: Die mediane Nachbeobachtungszeit betrug 37 Monate (17±60), die lokale Kontrollrate nach 4 Jahren und die Gesamtüberlebenszeit betrugen 87,5 ± 12% bzw. 888,9 ± 11%. Ein Patient erlitt ein Lokalrezidiv im CTV. Ein Patient verstarb an einer interkurrenten Erkrankung. Ein komplettes oder partielles Ansprechen wurde bei den meisten Patienten gesehen. Radiologisch ergaben sich elf stabilisierte Erkrankungsverläufe und fünf partielle Rückbildungen. In 12/15 Rezidivfällen bestand ein längeres krankheitsfreies Intervall nach der Bestrahlung als nach der initialen Operation. Die Bestrahlung wurde gut toleriert. Schlussfolgerungen: Die meisten Patienten mit gutartigen und aggressiveren Meningeomen zeigen sowohl ein klinisches Ansprechen als auch eine radiologische Langzeitstabilisation nach Erhöhung der Dosis um 10-15% bei einer konformalen Bestrahlung kombiniert mit Photonen und Protonen.
- Published
- 2002
- Full Text
- View/download PDF
11. Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: the Centre de Protonthérapie D’Orsay experience
- Author
-
Noël, Georges, Habrand, Jean-Louis, Mammar, Hamid, Pontvert, Dominique, Haie-Méder, Christine, Hasboun, Dominique, Moisson, Patricia, Ferrand, Régis, Beaudré, Anne, Boisserie, Gilbert, Gaboriaud, Geneviève, Mazal, Alexandre, Kérody, Katia, Schlienger, Michel, and Mazeron, Jean-Jacques
- Abstract
Purpose:Prospective analysis of local tumor control, survival, and treatment complications in 44 consecutive patients treated with fractionated photon and proton radiation for a chordoma or chondrosarcoma of the skull base.
- Published
- 2001
- Full Text
- View/download PDF
12. Proton beam therapy (PT) in the management of CNS tumors in childhood
- Author
-
Habrand, Jean-Louis, Mammar, Hamid, Ferrand, Régis, Pontvert, Dominique, Bondiau, Pierre, Kalifa, Chantal, and Zucker, Jean
- Abstract
Abstract: At the Centre de Protontherapie d’Orsay, nine children with intra-cranial malignancies were treated between July 1994 and January 1998. Immediate and late tolerances were excellent in all cases (follow-up 2 to 50 months). Two patients recurred locally (marginal failures), seven are alive and doing well. At Loma Linda, 28 children were treated between 1991 and 1994, 16 for a benign tumor of the brain and twelve for a malignant one. With a follow-up of seven to 49 months, three patients died (grade 2 to 4 gliomas), one is living with a persistant disease. Four children had treatment — related toxicity (one cataract, two hormonal failures and two seizures). The other children are doing well. At MGH Boston, 18 children with skull base-cervical spine chordomas have been reported. At five years, actuarial survival and disease-free survival have been 68 and 63%, respectively. Children with cervical sites had a worse prognosis (p=0.008). Four children had radiaton-related morbidity: two pituitary failures, one temporal lobe necrosis, one temporal muscle fibrosis. In this experience, such rare tumors seemed to behave in children like in adults.
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.